2025
Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes
Zohora F, Nazari M, Sinusas A. Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes. Current Cardiology Reports 2025, 27: 61. PMID: 40009333, DOI: 10.1007/s11886-025-02197-9.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter defibrillatorPositron emission tomographyImplantable cardioverter defibrillator placementMyocardial sympathetic denervationRisk stratificationSympathetic denervationIschemic heart diseaseHeart failurePrevention of sudden cardiac deathRisk stratification of patientsHeart diseaseOptimal risk stratificationLow ejection fractionStratification of patientsSympathetic nerve densityImprove risk stratificationHeart failure patientsPositron emission tomography radiotracersPredicting sudden cardiac deathPositron emission tomography tracersPrognostic benefitEjection fractionClinically practical approachNerve density
2024
Head and neck tumor segmentation from [18F]F-FDG PET/CT images based on 3D diffusion model
Dong Y, Gong K. Head and neck tumor segmentation from [18F]F-FDG PET/CT images based on 3D diffusion model. Physics In Medicine And Biology 2024, 69: 155001. PMID: 38959909, PMCID: PMC11302413, DOI: 10.1088/1361-6560/ad5ef2.Peer-Reviewed Original ResearchMeSH KeywordsDiffusionFluorodeoxyglucose F18Head and Neck NeoplasmsHumansImaging, Three-DimensionalPositron Emission Tomography Computed TomographyConceptsTumor segmentationNetwork inputState-of-the-art techniquesState-of-the-artAccurate segmentation resultsSingle-modal dataPET/CT imagingCancer managementChallenge datasetSegmentation masksCT volumesUNet structureSegmentation resultsU-NetCT imagesDiffusion modelCT dataReversal processPrevalent typeTumor maskQuantitative metricsTumorProposed diffusion modelCTNoise volumeTumors Affect the Metabolic Connectivity of the Human Brain Measured by 18F-FDG PET
Pasquini L, Jenabi M, Graham M, Peck K, Schöder H, Holodny A, Krebs S. Tumors Affect the Metabolic Connectivity of the Human Brain Measured by 18F-FDG PET. Clinical Nuclear Medicine 2024, 49: 822-829. PMID: 38693648, PMCID: PMC11300165, DOI: 10.1097/rlu.0000000000005227.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBrainBrain NeoplasmsFemaleFluorodeoxyglucose F18GliomaHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyRetrospective StudiesConceptsHealthy controlsTemporal tumorF-FDGFrontal tumorF-FDG PET/MRIKarnofsky performance scoreF-FDG PETHigh-grade gliomasLow-grade gliomasLow KPSRadiation necrosisActive tumorMetabolic brain networkMetabolic connectivityHigher KPSBrain metabolic connectivityHemispheric tumorsLow-gradeSignificant hemispheric differencesSynaptic activityTumorPatientsBetweenness centralityLeft hemisphere tumorsGlucose metabolismIdentifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography
Okamoto M, Yamaguchi S, Sawaya R, Echizenya S, Ishi Y, Kaneko S, Motegi H, Toyonaga T, Hirata K, Fujimura M. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography. BioMed Research International 2024, 2024: 2973407. PMID: 38449509, PMCID: PMC10917478, DOI: 10.1155/2024/2973407.Peer-Reviewed Original ResearchConceptsPositron emission tomographyF-FDGMRNA expressionOverall survivalGlucose metabolismF-FDG positron emission tomographyAssociated with poor overall survivalProtein expressionEmission tomographyGross total resectionPotential key moleculesFluorine-18 fluorodeoxyglucoseHypoxic conditionsDegree of glucose metabolismMolecular mechanisms of glucose metabolismAggressive primary brain tumorPoor overall survivalPrimary brain tumorKey moleculesTotal resectionPreoperative examinationIntratumoral hypoxiaPrognostic valuePoor prognosisBiomarkers of glioblastomaA pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
van Dyck C, Mecca A, O’Dell R, Bartlett H, Diepenbrock N, Huang Y, Hamby M, Grundman M, Catalano S, Caggiano A, Carson R. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 20. PMID: 38273408, PMCID: PMC10809445, DOI: 10.1186/s13195-024-01382-2.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyloid beta-PeptidesAnimalsBiomarkersFluorodeoxyglucose F18HumansMicePilot ProjectsPositron-Emission TomographyConceptsMild to moderate dementiaPositron emission tomographyAlzheimer's diseaseVolumetric MRIModerate dementiaClinical rating scalesSynaptic vesicle glycoprotein 2ACerebrospinal fluidMouse model of ADPharmacodynamic effectsPlacebo-controlled phase 1 clinical trialBiomarkers of AD pathologyClinical trialsCognitive measuresNominally significant differencesPhase 1 clinical trialModel of ADHippocampal cortexPhase 1/2 studyRating ScaleParallel-group trialSynaptic densityTrial registrationThe clinical trialPlacebo-controlledSigma-2 receptor ligands
2023
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Cimino-Mathews A, Wahl R, Stearns V, Connolly R. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). Journal Of Nuclear Medicine 2023, 64: jnumed.123.265853. PMID: 37652539, DOI: 10.2967/jnumed.123.265853.Peer-Reviewed Original ResearchConceptsF-FDG PET/CTHER2-positive breast cancerRecurrence-free survivalPET/CTPathologic complete responseOverall survivalBreast cancerOperable HER2-positive breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Kaplan-Meier methodStatistical significanceLean body massFactor receptor 2Imaging-based biomarkersCorrelation of SUVHER2 therapyNeoadjuvant trastuzumabNeoadjuvant therapyAdjuvant therapyComplete responsePhysician's discretionOS outcomesCox regressionPost-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity
Yu Y, Schöder H, Zakeri K, Chen L, Kang J, McBride S, Tsai C, Gelblum D, Boyle J, Cracchiolo J, Cohen M, Singh B, Ganly I, Patel S, Michel L, Dunn L, Sherman E, Pfister D, Wong R, Riaz N, Lee N. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity. Oral Oncology 2023, 141: 106400. PMID: 37099979, PMCID: PMC10631462, DOI: 10.1016/j.oraloncology.2023.106400.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaIntermediate-risk featuresPET/CTHigh-risk featuresPost-operative radiationSquamous cell carcinomaEarly recurrenceRisk featuresSurgical marginsCell carcinomaPET/CT planningAddition of chemotherapyClose surgical marginsDisease-free survivalPositive surgical marginsRecords of patientsPositron emission tomographyTreatment intensificationBaseline characteristicsNode positivityLymphovascular invasionOverall survivalPT3-4Perineural invasionTumor thicknessBaseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUVImportance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy
Hoppe B, McCarten K, Pei Q, Kessel S, Alazraki A, Mhlanga J, Lai H, Eutsler E, Hodgson D, Roberts K, Charpentier A, Keller F, Voss S, Wu Y, Cho S, Kelly K, Castellino S. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: 1025-1030. PMID: 36868525, PMCID: PMC10363760, DOI: 10.1016/j.ijrobp.2023.02.020.Peer-Reviewed Original ResearchMeSH KeywordsChildFluorodeoxyglucose F18Hodgkin DiseaseHumansPositron Emission Tomography Computed TomographyPositron-Emission TomographyConceptsCentral reviewDeauville scoreCentral imaging reviewRadiation therapyResponse assessmentHodgkin's lymphomaImaging reviewInstitutional reviewFluorodeoxyglucose positron emission tomography/High-risk Hodgkin lymphomaPositron emission tomography responseConcordance rateEmission tomography/Real-time central reviewCohen κ statisticAreas of diseaseSystemic therapyTreating institutionPediatric patientsLymphoma trialsTomography responseTomography/Treatment allocationClinical trialsPatientsDeep learning-based attenuation map generation with simultaneously reconstructed PET activity and attenuation and low-dose application
Shi L, Zhang J, Toyonaga T, Shao D, Onofrey J, Lu Y. Deep learning-based attenuation map generation with simultaneously reconstructed PET activity and attenuation and low-dose application. Physics In Medicine And Biology 2023, 68: 035014. PMID: 36584395, DOI: 10.1088/1361-6560/acaf49.Peer-Reviewed Original ResearchIn vivo imaging of cerebral glucose metabolism informs on subacute to chronic post-stroke tissue status – A pilot study combining PET and deuterium metabolic imaging
Meerwaldt A, Straathof M, Oosterveld W, van Heijningen C, van Leent M, Toner Y, Munitz J, Teunissen A, Daemen C, van der Toorn A, van Vliet G, van Tilborg G, De Feyter H, de Graaf R, Hol E, Mulder W, Dijkhuizen R. In vivo imaging of cerebral glucose metabolism informs on subacute to chronic post-stroke tissue status – A pilot study combining PET and deuterium metabolic imaging. Cerebrovascular And Brain Metabolism Reviews 2023, 43: 778-790. PMID: 36606595, PMCID: PMC10108187, DOI: 10.1177/0271678x221148970.Peer-Reviewed Original ResearchConceptsTransient middle cerebral artery occlusionPositron emission tomographyGlucose metabolismPost-ischemic brain tissueMiddle cerebral artery occlusionFDG positron emission tomographyFluorodeoxyglucose positron emission tomographyMetabolic imagingSignificant glial activationAcute ischemic strokeCerebral artery occlusionCerebral energy metabolismDeuterium metabolic imagingActive glucose metabolismGlial activationRecanalization therapyArtery occlusionIschemic strokeStroke severityCerebral perfusionC57BL/6 micePoor outcomeElevated lactate productionPathophysiological changesBaseline values
2022
Real-world assessment of the clinical utility of whole body 18F-FDG PET/CT in the diagnosis of infection.
Medvedeva N, Radcliffe C, Malinis M, Chen M, Azar M. Real-world assessment of the clinical utility of whole body 18F-FDG PET/CT in the diagnosis of infection. PLOS ONE 2022, 17: e0277403. PMID: 36374789, PMCID: PMC9662742, DOI: 10.1371/journal.pone.0277403.Peer-Reviewed Original ResearchConceptsPET/CTClinical impactFDG PET/CTRetrospective chart reviewEmission tomography/Evaluation of infectionDiagnosis of infectionVariety of syndromesInfectious indicationsChart reviewCommon indicationTomography useUnknown etiologyEndovascular infectionTomography/Antimicrobial managementClinical indicationsReal-world assessmentInclusion criteriaClinical utilityPatientsTreatment managementUnknown originInfectionCTFull automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
Jemaa S, Paulson J, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano R, El-Galaly T, Nielsen T, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging 2022, 22: 39. PMID: 35962459, PMCID: PMC9373298, DOI: 10.1186/s40644-022-00476-0.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaProgression-free survivalOverall survivalFDG-PETUntreated diffuse large B-cell lymphomaHazard ratioHigh-risk DLBCL patientsCentral nervous system relapseLarge B-cell lymphomaMetabolic tumor volumeImaging-based risk factorsB-cell lymphomaEnhanced risk stratificationHigh-risk populationImaging metricsRisk increaseDLBCL patientsFDG-PET/CTSystemic relapseTumor volumeOrgan involvementPrognostic improvementRisk stratificationInvasive proceduresClinical dataMolecular Imaging in Acute Aortic Syndrome Lighting a Path to Better Risk Assessment ∗
Tawakol A, Mezue K. Molecular Imaging in Acute Aortic Syndrome Lighting a Path to Better Risk Assessment ∗. JACC Cardiovascular Imaging 2022, 15: 1305-1307. PMID: 35798406, DOI: 10.1016/j.jcmg.2022.04.022.Peer-Reviewed Original ResearchIdentifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging
Sun T, Wang Z, Wu Y, Gu F, Li X, Bai Y, Shen C, Hu Z, Liang D, Liu X, Zheng H, Yang Y, El Fakhri G, Zhou Y, Wang M. Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 49: 2994-3004. PMID: 35567627, PMCID: PMC9106794, DOI: 10.1007/s00259-022-05832-7.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19Fluorodeoxyglucose F18HumansLung NeoplasmsPositron-Emission TomographyWhole Body ImagingConceptsPET imagingNormal control databaseTotal-body imagingWhole-body PET imagingNon-invasive modalitySUV measurementsGastrointestinal bleedingMetabolic abnormitiesSystem abnormalitiesTotal bodyLung cancerHealthy subjectsMetabolic dysfunctionFocal lesionsCOVID-19 diseaseGlucose metabolismControl databaseSUV imagesPatientsAbnormal networkBiological mechanismsDiseasePETMetabolic connectivityJoint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0
Piccardo A, Albert N, Borgwardt L, Fahey F, Hargrave D, Galldiks N, Jehanno N, Kurch L, Law I, Lim R, Lopci E, Marner L, Morana G, Young Poussaint T, Seghers V, Shulkin B, Warren K, Traub-Weidinger T, Zucchetta P. Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 49: 3852-3869. PMID: 35536420, PMCID: PMC9399211, DOI: 10.1007/s00259-022-05817-6.Peer-Reviewed Original ResearchMeSH KeywordsAmino AcidsChildFluorodeoxyglucose F18GliomaHumansPositron-Emission TomographyRadiopharmaceuticalsConceptsAmino acid positron emission tomographyPositron emission tomographyPaediatric neuro-oncologyEuropean Society for Paediatric Oncology (SIOPENeuro-oncologyLevel of evidenceBrain tumor groupPositron emission tomography imagingEvidence-based recommendationsPaediatric patientsTumor groupResponse assessmentClinician guidelinesPaediatric gliomasBrain gliomasImaging specialistsEmission tomographyRadiolabeled amino acidsConsensus opinionEANMPaediatric oncologyPET radiopharmaceuticalsGliomaNuclear medicineOncologyDeep learning–based attenuation correction for whole-body PET — a multi-tracer study with 18F-FDG, 68 Ga-DOTATATE, and 18F-Fluciclovine
Toyonaga T, Shao D, Shi L, Zhang J, Revilla EM, Menard D, Ankrah J, Hirata K, Chen MK, Onofrey JA, Lu Y. Deep learning–based attenuation correction for whole-body PET — a multi-tracer study with 18F-FDG, 68 Ga-DOTATATE, and 18F-Fluciclovine. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 49: 3086-3097. PMID: 35277742, PMCID: PMC10725742, DOI: 10.1007/s00259-022-05748-2.Peer-Reviewed Original ResearchConceptsNeural networkNovel deep learningNet neural networkPET/CT datasetsImage analysis metricsPhysics-based loss functionDeep learningCT-derived attenuation mapAttenuation mapLoss functionAnalysis metricsDetail recoveryTumor volume estimationMLAACT datasetsOSEM algorithmNetworkAlgorithmAttenuation correctionCorrection frameworkPrediction of cardiac events following concurrent chemoradiation therapy for non-small-cell lung cancer using FDG PET
Cho S, Kim Y, Park H, Park K, Kim J, Ahn S, Bom H. Prediction of cardiac events following concurrent chemoradiation therapy for non-small-cell lung cancer using FDG PET. Annals Of Nuclear Medicine 2022, 36: 439-449. PMID: 35175561, DOI: 10.1007/s12149-022-01724-w.Peer-Reviewed Original ResearchConceptsNon-small-cell lung cancerConcurrent chemoradiation therapyPrediction of cardiac eventsStandardized uptake valueLate cardiac eventsCardiac eventsFDG-PETHeart doseChemoradiation therapyTumor stageUnresectable stage III non-small-cell lung cancerStage III non-small-cell lung cancerIII non-small-cell lung cancerLung cancerF-18 fluorodeoxyglucose positron emission tomographyGrade 2Common Terminology Criteria for Adverse EventsPredicting late cardiac eventsPredictor of cardiac eventsRisk of cardiac eventsAssociated with cardiac eventsLeft ventricular (LVFluorodeoxyglucose positron emission tomographyMean heart doseMedian follow-upPrecise characterization of a solitary pulmonary nodule using tumor shadow disappearance rate-corrected F-18 FDG PET and enhanced CT
Park K, Seon H, Yun J, Yoo S, Lee C, Kang S, Kim J, Cho S, Song H, Bom H, Min J, Kwon S. Precise characterization of a solitary pulmonary nodule using tumor shadow disappearance rate-corrected F-18 FDG PET and enhanced CT. Medicine 2022, 101: e28764. PMID: 35119036, PMCID: PMC8812657, DOI: 10.1097/md.0000000000028764.Peer-Reviewed Original ResearchMeSH KeywordsFluorodeoxyglucose F18HumansLung NeoplasmsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective StudiesSolitary Pulmonary NoduleConceptsTumor shadow disappearance rateSolitary pulmonary nodulesF-18 fluorodeoxyglucoseCharacterization of SPNsEnhanced CTPulmonary nodulesTumor areaHigh value of SUVmaxF-18 FDG PETPositron emission tomography/computed tomographyF-18 fluorodeoxyglucose uptakeImaging parametersValue of SUVmaxEmission tomography/computed tomographyStandardized uptake valueTissue densityPost-enhanced CTEnhanced CT imagesPreenhancement CTTomography/computed tomographyChest CTLung windowMediastinal windowUptake valueFDG-PET
2021
FDG PET vascular imaging in IgG4-RD: Potential and challenges
Pucar D, Hinchcliff M. FDG PET vascular imaging in IgG4-RD: Potential and challenges. Journal Of Nuclear Cardiology 2021, 29: 2934-2937. PMID: 34964084, DOI: 10.1007/s12350-021-02887-1.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply